Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
Researchers are evaluating the safety and efficacy of ibuzatrelvir alone and in combination with remdesivir compared to remdesivir alone in treating symptomatic COVID-19 among severely immunocompromised adults. This Phase 3, randomized, double-blind study focuses on participants who are non-hospitalized or have mild-to-moderate COVID-19 at baseline. The trial aims to better understand treatment options for this vulnerable patient group who may face prolonged infections and severe illness progression. Participants are assigned to one of three groups ibuzatrelvir taken orally twice daily plus intravenous remdesivir, ibuzatrelvir plus intravenous placebo, or oral placebo plus intravenous remdesivir. The study uses matching placebos to maintain blinding. Treatment durations and specific dosing schedules are carefully monitored to compare the combination and monotherapy effects over the study period. During approximately 10 study visits over 24 weeks, participants will attend clinic visits for blood tests, nasal swabs collected both in-clinic and at home, and complete questionnaires. Researchers will assess outcomes such as symptom alleviation, viral RNA levels, rates of infection recurrence, hospital visits, and safety events. This comprehensive monitoring helps evaluate the impact of the treatments on COVID-19 symptoms and viral clearance in immunocompromised adults.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.